Eisai Plans to Submit Product management Authorization Applications for Eribulin Mesylate in Locally Advanced or Metastatic Breast Cancer WOODCLIFF LAKE, N.J., Oct. Thirty (HSMN NewsFeed) — Eisai Inc. today announced preliminary results from a recently completed …
Biopharmacetuicals, Onocology
Eisai, eribulin mesylate, breast cancer

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival”
Leave a Comment